# Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer

> **NCT02418247** · PHASE2,PHASE3 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 556 (estimated)

## Conditions studied

- Thyroid Neoplasms

## Interventions

- **DRUG:** I131
- **DRUG:** I123

## Key facts

- **NCT ID:** NCT02418247
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2017-12
- **Final completion:** 2020-12
- **Target enrollment:** 556 (ESTIMATED)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02418247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02418247, "Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02418247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*